Allogene Therapeutics, INC Form 4 insider transactions

Allogene Therapeutics, Inc. reports that President and CEO Zachary Roberts acquired a significant number of Restricted Stock Units and Stock Options.

Allogene Therapeutics SVP of Finance Annie Yoshiyama sold shares to cover tax withholding obligations upon vesting of restricted stock units.

Allogene Therapeutics reports a "sell to cover" transaction by SVP, Chief Technical Officer Benjamin Machinas to satisfy tax withholding obligations upon vesting of restricted stock units.

Allogene Therapeutics' SVP and Chief Technical Officer, Benjamin Beneski, sold 4,835 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics' President and CEO, David D. Chang, sold 47,763 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Allogene Therapeutics' SVP, Chief Technical Officer, Benjamin Beneski, sold 7,132 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics' SVP, Chief Technical Officer, Benjamin Beneski, sold shares to cover tax obligations and was granted new stock options and restricted stock units.

Allogene Therapeutics' President and CEO, David D. Chang, reported a non-discretionary sale of shares to cover tax obligations, alongside new grants of stock options and restricted stock units.

Allogene Therapeutics' CFO, Geoffrey M. Parker, reported a 'sell to cover' stock sale and new equity awards, including stock options and restricted stock units.

Allogene Therapeutics' SVP, General Counsel, Douglas Earl Martin, sold shares to cover tax obligations while simultaneously receiving new stock option and restricted stock unit awards.

Allogene Therapeutics' SVP of Finance, Annie Yoshiyama, reported a 'sell to cover' transaction and received new equity grants.

Allogene Therapeutics' EVP of R&D, Zachary Roberts, sold 35,700 shares to cover tax obligations while simultaneously receiving new stock options and restricted stock units.

Allogene Therapeutics Director Arie Belldegrun reported significant new equity awards, including stock options and restricted stock units, alongside existing indirect and direct common stock holdings.

Allogene Therapeutics' EVP of R&D, Zachary Roberts, sold 26,269 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics Director Joshua Kazam acquired 47,700 shares of common stock through the vesting of restricted stock units, correcting a prior reporting error.

Allogene Therapeutics' SVP, Chief Technical Officer, Benjamin Beneski, sold 786 shares of common stock at a weighted average price of $1.22 to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics' CFO, Geoffrey M. Parker, sold 36,744 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics, Inc. Director Vicki L. Sato was granted 144,400 stock options with an exercise price of $1.29, vesting over 12 months.

Allogene Therapeutics, Inc. Director Deborah M. Messemer was granted 95,400 Restricted Stock Units, vesting over one year, as disclosed in a recent SEC Form 4 filing.

Allogene Therapeutics, Inc. Director Franz B. Humer was granted 95,400 Restricted Stock Units (RSUs) on June 18, 2025, as part of his compensation.

Allogene Therapeutics, Inc. Director Elizabeth A. Barrett was granted 95,400 Restricted Stock Units, aligning her interests with long-term shareholder value.

Allogene Therapeutics, Inc. Director Stephen Mayo was granted 95,400 Restricted Stock Units, which will vest over one year, with receipt of shares deferred.

Allogene Therapeutics, Inc. Director Owen N. Witte was granted 95,400 Restricted Stock Units (RSUs) on June 18, 2025, as disclosed in a recent SEC Form 4 filing.

Allogene Therapeutics, Inc. Director and 10% owner Joshua A. Kazam has been granted 94,500 Restricted Stock Units (RSUs) as part of his compensation, aligning his interests with shareholders.

Deborah M. Messemer, a Director at Allogene Therapeutics, Inc., reported the sale of 36,885 shares of common stock for approximately $52,376 under a Rule 10b5-1 trading plan.

Annie Yoshiyama, SVP of Finance at Allogene Therapeutics, sold 9,601 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Allogene Therapeutics CEO David Chang sold 46,668 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics, sold 5,488 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics, acquired shares and stock options on March 1, 2025.

Deborah M. Messemer, a director at Allogene Therapeutics, sold 13,313 shares of common stock at an average price of $2.43 per share on February 18, 2025, under a pre-arranged Rule 10b5-1 trading plan.